Evidence map›Paper›PMID 34337679›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2021

PK/PD modeling of daptomycin against MRSA and MRSE and Monte Carlo simulation for bacteremia treatment.

Bruna Menezes, Izabel Alves, Keli Staudt, Betina Beltrame, Lessandra Michelin, Bibiana Verlindo de Araújo, Leandro Tasso

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bruna MenezesPrograma de Pós-Graduação Em Biotecnologia, Universidade de Caxias Do Sul, Caxias do Sul, Brazil.
Izabel AlvesPrograma de Pós-Graduação Em Ciências Farmacêuticas, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
Keli StaudtPrograma de Pós-Graduação Em Ciências Farmacêuticas, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
Betina BeltrameCurso de Farmácia, Universidade de Caxias Do Sul, Caxias do Sul, Brazil.
Lessandra MichelinPrograma de Pós-Graduação Em Ciências da Saúde, Universidade de Caxias Do Sul, Rua Francisco Getúlio Vargas, Caxias do Sul, 1130, 95070-560, Brazil.
Bibiana Verlindo de AraújoPrograma de Pós-Graduação Em Ciências Farmacêuticas, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
Leandro TassoPrograma de Pós-Graduação Em Biotecnologia, Universidade de Caxias Do Sul, Caxias do Sul, Brazil. ltasso@ucs.br.ORCID http://orcid.org/0000-0001-7102-9204
Universidade de Caxias do Sul · BRUniversidade Federal do Rio Grande · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to investigate the effect of daptomycin against methicillin-resistant staphylococci (MRSA and MRSE) bacteremia using computer modeling.

methodsA pharmacokinetic/pharmacodynamic (PK/PD) modeling strategy to explain the data from an in vitro dynamic model employing time-kill curves for MRSA and MRSE was proposed. Bacterial killing was followed over time by determining viable counts and the resulting time-kill data was analyzed. Monte Carlo simulations were performed using pharmacokinetic parameters and pharmacodynamic data to determine the probabilities of target attainment and cumulative fractions of response in terms of area under the concentration curve/minimum inhibition concentration (MIC) targets of daptomycin. Simulations were conducted to assess the reduction in the number of colony-forming units (CFU)/mL for 18 days of treatment with daptomycin at doses of 6, 8, and 10 mg/kg/24 h or 48 h with variations in creatinine clearance (CL

resultsMonte Carlo simulations showed that for MRSA there was a reduction > 2 log CFU/mL with doses ≥ 6 mg/kg/day in 75th percentile of the simulated population after 18 days of treatment with daptomycin, whereas for MRSE this reduction was observed in 95th percentile of the population.

conclusionsThe presented in vitro PK/PD model and associated modeling approach were able to characterize the time-kill kinetics of MRSA and MRSE. Our study based on PTAs suggests that doses ≥ 6 mg/kg/day of daptomycin should be used to treat bacteremia caused by MRSA and MRSE in patients with CL

Indexed as

BacteremiaDaptomycinMethicillin-Resistant Staphylococcus aureusMonte Carlo MethodStaphylococcal InfectionsAnti-Bacterial AgentsHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsDaptomycinBacteremiaDaptomycinMonte Carlo simulationPK/PD modeling

Identifiers

PMID34337679
PMCPMC8578253
OpenAlexW3187875109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.